💓 Intravenous route

💓 Milrinone is administered by the intravenous (IV) route because it is used for short-term management of acute decompensated heart failure and requires rapid, controlled delivery.

💓 It is a phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation, helping improve cardiac output.

💓 IV administration allows close titration based on the client’s hemodynamic status, blood pressure, heart rhythm, and clinical response.

💓 The nurse should use an infusion pump and monitor for changes in heart rate, blood pressure, urine output, and signs of improved perfusion.

💓 Milrinone is not given orally or sublingually for acute hospital management because it requires controlled IV infusion and close monitoring.

💓 Ventricular dysrhythmias

💓 The nurse should monitor for ventricular dysrhythmias because milrinone can increase myocardial excitability.

💓 Dysrhythmias are a serious adverse effect and may appear as premature ventricular contractions, ventricular tachycardia, or other abnormal rhythms.

💓 Continuous or frequent ECG monitoring is important, especially in clients with heart failure or electrolyte imbalances.

💓 The nurse should also monitor potassium and magnesium levels, because abnormalities can increase dysrhythmia risk.

💓 Any new irregular rhythm, palpitations, chest discomfort, worsening hypotension, or decreased perfusion should be reported promptly.

❌ Sublingual route

❌ Milrinone is not administered sublingually because this route is not appropriate for controlled inotropic infusion therapy.

❌ Sublingual medications are usually used when rapid absorption through oral mucosa is needed, such as certain forms of nitroglycerin.

❌ Oral route

❌ Oral milrinone is not the standard route for acute care use because the medication requires careful IV titration and monitoring.

❌ Giving it orally would not provide the controlled effect needed for unstable cardiac clients.

❌ Hypertension

❌ Hypertension is not the priority adverse effect because milrinone causes vasodilation, which is more likely to lower blood pressure.

❌ The nurse should monitor for hypotension, not hypertension.

❌ Bradycardia

❌ Bradycardia is not the most expected serious concern with milrinone.

❌ Milrinone may increase heart activity and is more associated with tachycardia and ventricular dysrhythmias.

🟠 "I should increase my fiber intake when taking this drug."

🟠 Calcium channel blockers (CCBs) may cause constipation, especially medications such as verapamil.

🟠 Increasing dietary fiber intake, fluids (if not restricted), and activity can help reduce this side effect.

🟠 Foods rich in fiber include fruits, vegetables, whole grains, and legumes.

🟠 Preventing constipation improves comfort and medication adherence.

🟠 This statement demonstrates correct understanding of patient teaching.

🟠 "Palpitations should be reported to the healthcare provider."

🟠 Clients taking calcium channel blockers should report palpitations, irregular heartbeat, worsening chest discomfort, or dizziness.

🟠 Some calcium channel blockers can affect cardiac conduction and heart rhythm.

🟠 Palpitations may indicate medication effects requiring evaluation.

🟠 Monitoring cardiovascular symptoms supports early identification of complications.

🟠 This statement reflects safe medication use.

🟠 "Grapefruit juice can increase drug levels and effects."

🟠 Grapefruit juice may inhibit drug metabolism enzymes (CYP3A4), causing increased blood levels of certain calcium channel blockers.

🟠 Increased medication levels raise the risk of hypotension, dizziness, edema, and adverse effects.

🟠 Clients should consult the healthcare provider before consuming grapefruit products.

🟠 Medication-food interactions are important components of patient education.

🟠 This statement demonstrates accurate understanding.

❌ "I should take this medication only if I am symptomatic."

❌ Calcium channel blockers should generally be taken as prescribed, not only when symptoms occur.

❌ Skipping doses may reduce effectiveness and lead to poor blood pressure or symptom control.

❌ "A rash is a harmless side effect of this medication."

❌ A rash may indicate an allergic reaction or adverse drug response and should not be ignored.

❌ Clients should report new skin reactions for evaluation.

❤️ Metoprolol is a beta₁-selective adrenergic blocker (beta blocker) used as adjunct therapy in heart failure to reduce workload on the heart and improve long-term cardiac function.

❤️ It works by slowing the heart rate, decreasing myocardial contractility, and lowering oxygen demand, allowing the heart to pump more efficiently.

❤️ Over time, metoprolol helps reduce harmful effects of chronic sympathetic nervous system stimulation, which contributes to heart failure progression.

❤️ Benefits may include improved symptoms, reduced hospitalizations, improved ejection performance, and increased survival when used appropriately.

❤️ Clients should understand that metoprolol is usually taken consistently and should not be stopped abruptly.

❌ "Metoprolol helps to remove all of the excess fluid in my body."

❌ Removal of excess fluid is primarily the role of diuretics, not metoprolol.

❌ Metoprolol mainly affects heart rate and cardiac workload, not direct fluid elimination.

❌ "Metoprolol helps block the hormone aldosterone to reduce fluid retention."

❌ Blocking aldosterone is the action of aldosterone antagonists such as spironolactone.

❌ Metoprolol works through beta-adrenergic receptor blockade, not hormonal blockade.

❌ "Metoprolol helps to improve my kidney function to remove wastes."

❌ Metoprolol is not prescribed to improve kidney filtration or waste removal.

❌ Its primary therapeutic effect is on the cardiovascular system.

🫀 Amlodipine is a calcium channel blocker that lowers blood pressure by causing vasodilation and decreasing peripheral vascular resistance.

🫀 A blood pressure of 88/64 mm Hg indicates hypotension, and administering amlodipine could worsen the low blood pressure and reduce tissue perfusion.

🫀 Giving the medication in this situation may increase the risk of dizziness, syncope, decreased organ perfusion, and cardiovascular instability.

🫀 The nurse should hold the medication, reassess the client, and notify the healthcare provider before administration.

🫀 Medication administration should always include assessment of current vital signs and hemodynamic stability.

❌ The client's feet are slightly edematous.

❌ Mild peripheral edema is a known side effect of amlodipine due to vasodilation.

❌ Although it should be monitored, slight edema alone is not an immediate reason to hold the medication.

❌ The client is diagnosed with hypertension.

❌ Hypertension is one of the common indications for prescribing amlodipine.

❌ This finding supports rather than contraindicates medication use.

❌ The client denies feeling chest pain currently.

❌ Amlodipine is often taken on a scheduled basis to prevent angina episodes, not only during active chest pain.

❌ Absence of chest pain does not mean the medication should be withheld.

🩸 Warfarin is an anticoagulant that requires monitoring using prothrombin time (PT) and international normalized ratio (INR) to evaluate clotting status and determine whether excessive anticoagulation is contributing to bleeding.

🩸 This client presents with persistent epistaxis (nosebleed) for 4 hours despite pressure, which raises concern for an elevated INR and increased bleeding risk.

🩸 The priority nursing action is to obtain laboratory data to assess the severity of anticoagulation and guide treatment decisions.

🩸 Depending on the INR result and severity of bleeding, the provider may adjust warfarin therapy or prescribe reversal treatment.

🩸 Monitoring for additional bleeding signs such as bruising, hematuria, melena, hypotension, or tachycardia is also important.

❌ Apply a warm compress to the nose

❌ Warm compresses promote vasodilation, which may worsen bleeding rather than control it.

❌ Nosebleeds are generally managed initially with pressure and sometimes cold application—not heat.

❌ Administer intravenous alteplase

❌ Alteplase is a thrombolytic medication that dissolves clots and would significantly increase bleeding risk.

❌ It is contraindicated in a patient already experiencing active bleeding.

❌ Administer protamine sulfate

❌ Protamine sulfate is the reversal agent for heparin, not warfarin.

❌ Warfarin reversal typically involves vitamin K (phytonadione) and other measures depending on severity.

🧠 Montelukast is a leukotriene receptor antagonist commonly prescribed for asthma maintenance and allergic rhinitis.

🧠 An important adverse effect requiring immediate reporting is neuropsychiatric changes, including depression, mood changes, agitation, anxiety, sleep disturbances, suicidal thoughts, and behavioral changes.

🧠 Clients and families should be educated to monitor for emotional or behavioral changes after starting therapy.

🧠 Because these reactions can be serious, the client should contact the healthcare provider promptly if symptoms occur.

🧠 Montelukast is used for prevention and maintenance and should not be used to treat an acute asthma attack.

❌ Blurred vision

❌ Blurred vision is not a common or priority adverse effect associated with montelukast.

❌ Although vision changes should be evaluated if severe, they are not the primary teaching point.

❌ Palpitations

❌ Palpitations are not typically associated with montelukast therapy.

❌ Cardiovascular monitoring is not the main concern for this medication.

❌ Constipation

❌ Constipation is not a major adverse effect commonly emphasized during montelukast education.

❌ Neuropsychiatric symptoms are more clinically significant.

❤️ Hydralazine is a direct vasodilator that lowers blood pressure by relaxing vascular smooth muscle and reducing peripheral resistance.

❤️ Excessive hydralazine effects or toxicity can lead to reflex tachycardia, where the heart rate increases in response to vasodilation and falling blood pressure.

❤️ Clients may also experience palpitations, hypotension, flushing, headache, dizziness, and chest discomfort.

❤️ Tachycardia occurs because the body attempts to maintain adequate cardiac output after blood vessels dilate.

❤️ Nurses should monitor heart rate, blood pressure, and symptoms of cardiovascular instability during therapy.

❌ Constipation

❌ Constipation is not a typical finding associated with hydralazine toxicity.

❌ Hydralazine primarily affects the cardiovascular system rather than gastrointestinal motility.

❌ Hypertension

❌ Hydralazine lowers blood pressure, so toxicity is more associated with hypotension, not hypertension.

❌ Elevated blood pressure would suggest inadequate treatment rather than toxicity.

❌ Seizure

❌ Seizures are not a classic clinical finding of hydralazine toxicity.

❌ Cardiovascular effects such as reflex tachycardia are more expected.

🫀 Amlodipine is a calcium channel blocker (CCB) used to treat hypertension and angina by relaxing blood vessels and reducing peripheral vascular resistance.

🫀 One of the most common adverse effects is peripheral edema, especially swelling of the feet, ankles, and lower legs.

🫀 This occurs because vasodilation increases pressure within peripheral capillaries, causing fluid to move into surrounding tissues.

🫀 The nurse should monitor for ankle swelling, weight gain, tight shoes, and lower-extremity enlargement during therapy.

🫀 Clients should also be monitored for hypotension, dizziness, flushing, and headache.

❌ Respiratory infection

❌ Respiratory infection is not a typical adverse effect associated with amlodipine.

❌ Amlodipine primarily affects the cardiovascular system rather than increasing infection risk.

❌ Watery diarrhea

❌ Diarrhea is not a common or priority adverse reaction of amlodipine.

❌ Gastrointestinal symptoms are less characteristic than vascular effects.

❌ Hypertension

❌ Amlodipine is prescribed to lower blood pressure, not cause hypertension.

❌ The nurse is more concerned about hypotension than elevated blood pressure.

🟡 Fenofibrate is a fibric acid derivative used to lower triglycerides and cholesterol levels.

🟡 An important adverse reaction to monitor for is hepatotoxicity, which may present as jaundice (yellowing of the skin or eyes).

🟡 Jaundice can indicate liver dysfunction or impaired bile processing, requiring prompt evaluation by the healthcare provider.

🟡 Clients taking fenofibrate may require periodic monitoring of liver function tests (AST, ALT, bilirubin) during therapy.

🟡 The nurse should also monitor for symptoms such as dark urine, abdominal pain, fatigue, and unusual weakness.

❌ Blurry vision

❌ Blurry vision is not a common or hallmark adverse reaction associated with fenofibrate.

❌ Visual changes should still be evaluated but are not the priority concern.

❌ Hyperglycemia

❌ Fenofibrate is not primarily associated with causing elevated blood glucose levels.

❌ Monitoring focuses more on liver and muscle effects.

❌ Increased potassium

❌ Hyperkalemia is not a typical adverse effect of fenofibrate therapy.

❌ Electrolyte changes are not the major monitoring concern for this medication.